• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature clinical practice. Rheumatology >Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases.
【24h】

Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases.

机译：底漆：风湿性和全身性炎症性疾病的生物标志物的实际使用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The assessment of systemic inflammation by means of laboratory tests often complements the results of medical examination. Traditionally, the erythrocyte sedimentation rate and leukocytosis with left shift are diagnostic markers for inflammatory and infectious diseases. The levels of acute-phase proteins--especially C-reactive protein--are used to assess both the presence of inflammation and any response to treatment. The determination of C-reactive protein levels may be advised in three types of pathological situation: infection, acute or chronic inflammation, and evaluation of metabolic risk. Procalcitonin is useful as a marker of sepsis and severe infection. The concentration of serum amyloid A predicts the chances of survival of patients with secondary (AA) amyloidosis. Ferritin and its glycosylated form are of interest in the study of specific diseases such as adult-onset Still's disease. Markers of cartilage and bone turnover are complementary to these markers of inflammation. Although cytokine serum levels are transiently crucial to the generation of inflammation, their usefulness in the clinic is still under investigation. Serum concentrations of cytokine inhibitors or soluble cytokine receptors, as well as the clinical response of patients to treatment with cytokine antagonists, might generate important information for monitoring autoinflammatory diseases.
机译：通过实验室检查评估全身性炎症通常可以补充医学检查的结果。传统上，红细胞沉降率和左移的白细胞增多是炎性和感染性疾病的诊断标志。急性期蛋白（尤其是C反应蛋白）的水平用于评估炎症的存在和对治疗的任何反应。可以在三种类型的病理情况下建议确定C反应蛋白的水平：感染，急性或慢性炎症以及代谢风险的评估。降钙素原可用作败血症和严重感染的标志物。血清淀粉样蛋白A的浓度可预测继发性（AA）淀粉样变性病患者的生存机会。铁蛋白及其糖基化形式在特定疾病（例如成年性斯蒂尔氏病）的研究中受到关注。软骨和骨转换的标志物是这些炎症标志物的补充。尽管细胞因子血清水平对于炎症的产生是暂时性的，但其在临床上的有效性仍在研究中。血清中细胞因子抑制剂或可溶性细胞因子受体的浓度，以及患者对细胞因子拮抗剂治疗的临床反应，可能会为监测自身炎症性疾病提供重要信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号